Squarepoint Ops LLC lowered its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 20.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,173 shares of the medical instruments supplier's stock after selling 16,612 shares during the quarter. Squarepoint Ops LLC owned approximately 0.29% of LeMaitre Vascular worth $6,097,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. New York State Teachers Retirement System boosted its position in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after purchasing an additional 100 shares during the period. Flputnam Investment Management Co. boosted its position in LeMaitre Vascular by 3.6% during the 4th quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after purchasing an additional 102 shares during the period. Norden Group LLC boosted its position in LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock valued at $218,000 after purchasing an additional 103 shares during the period. Blue Barn Wealth LLC boosted its position in LeMaitre Vascular by 4.4% during the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after purchasing an additional 104 shares during the period. Finally, Shaker Investments LLC OH boosted its position in LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after purchasing an additional 112 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.
Analyst Ratings Changes
A number of research analysts have issued reports on LMAT shares. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price target for the company. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Lake Street Capital boosted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $98.14.
Read Our Latest Stock Report on LMAT
LeMaitre Vascular Price Performance
Shares of LeMaitre Vascular stock traded up $0.99 during trading on Friday, hitting $82.06. The stock had a trading volume of 30,712 shares, compared to its average volume of 167,634. The firm has a market cap of $1.85 billion, a P/E ratio of 44.73, a PEG ratio of 2.22 and a beta of 0.86. The business has a fifty day moving average of $84.02 and a two-hundred day moving average of $92.11. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58.
LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The company's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.44 EPS. As a group, research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's dividend payout ratio (DPR) is presently 40.40%.
Insider Transactions at LeMaitre Vascular
In other news, CEO George W. Lemaitre sold 18,733 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the sale, the chief executive officer now directly owns 1,873,651 shares of the company's stock, valued at $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Trent G. Kamke sold 2,009 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 102,009 shares of company stock valued at $8,721,836 over the last three months. Company insiders own 9.50% of the company's stock.
About LeMaitre Vascular
(
Free Report)
LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.
Further Reading
Before you consider LeMaitre Vascular, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.
While LeMaitre Vascular currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
